Thomas Babcock

Summary

Affiliation: Shire BioChem Inc

Publications

  1. ncbi Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study
    Thomas Babcock
    Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA
    BMC Pharmacol Toxicol 13:18. 2012
  2. ncbi Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
    Rakesh Jain
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, Texas, and R D Clinical Research, Inc, Lake Jackson, Texas, USA
    Child Adolesc Psychiatry Ment Health 5:35. 2011
  3. ncbi Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective
    Thomas Babcock
    Shire Pharmaceuticals, 725 Chesterbrook Road, Wayne, PA 19087 5637, USA
    Postgrad Med 121:73-82. 2009
  4. ncbi Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity
    Lawrence Ginsberg
    Red Oak Psychiatry Associates, PA, Houston, TX 77090, USA
    Curr Med Res Opin 27:1097-107. 2011

Collaborators

  • Lenard A Adler
  • Lawrence Ginsberg
  • Rakesh Jain
  • Ben Adeyi
  • Robert Lasser
  • Brian Scheckner
  • Bryan Dirks
  • Alain Katic
  • Teodor Burtea

Detail Information

Publications4

  1. ncbi Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study
    Thomas Babcock
    Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA
    BMC Pharmacol Toxicol 13:18. 2012
    ..Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, and electrocardiogram...
  2. ncbi Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
    Rakesh Jain
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, Texas, and R D Clinical Research, Inc, Lake Jackson, Texas, USA
    Child Adolesc Psychiatry Ment Health 5:35. 2011
    ..abstract:..
  3. ncbi Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective
    Thomas Babcock
    Shire Pharmaceuticals, 725 Chesterbrook Road, Wayne, PA 19087 5637, USA
    Postgrad Med 121:73-82. 2009
    ..Although rates of psychiatric comorbidity are high in adults with ADHD, available data suggest that the benefits of pharmacotherapy for ADHD are not compromised by the presence of psychiatric comorbidity...
  4. ncbi Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity
    Lawrence Ginsberg
    Red Oak Psychiatry Associates, PA, Houston, TX 77090, USA
    Curr Med Res Opin 27:1097-107. 2011
    ..To examine the impact of baseline severity on lisdexamfetamine dimesylate (LDX) efficacy in a long-term study of adults with attention-deficit/hyperactivity disorder (ADHD)...